Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109530 | 0.83 | SLC6A2 (0.46) | KMT2AMAPK1PLATHTR6L3MBTL1 | |
| SCHEMBL6109813 | 0.79 | ACHE (0.49) | KMT2AMAPK1HTR6L3MBTL1SLC6A2 | |
| SCHEMBL22324823 | 0.79 | ALDH1A1 (0.44) | KMT2AMAPK1PLATL3MBTL1KCNH2 | |
| SCHEMBL6251645 | 0.78 | L3MBTL1 (0.51) | KMT2AMAPK1HTR6L3MBTL1SLC6A2 | |
| SCHEMBL22324855 | 0.76 | L3MBTL1 (0.43) | PLATCCNT1CDK9HTR6L3MBTL1 | |
| SCHEMBL725693 | 0.75 | HDAC8 (0.51) | MAPK1KCNH2ACHE | |
| SCHEMBL725692 | 0.75 | HDAC8 (0.51) | MAPK1KCNH2ACHE | |
| SCHEMBL22324948 | 0.75 | L3MBTL1 (0.52) | PLATL3MBTL1ACHEHTR2CHTR2B | |
| SCHEMBL3169070 | 0.74 | KMT2A (0.48) | KMT2AMAPK1L3MBTL1KCNH2 | |
| SCHEMBL22324880 | 0.74 | CYP1A2 (0.46) | KMT2AMAPK1PLATSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012025155-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | NOVARTIS AG | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053925-A1 | Hydroxamate-Based Inhibitors of Deacetylases | HDAC1, HDAC11, HDAC3 | KMT2A 122/4885MAPK1 2473/4885DRD2 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.